Weizhi He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weizhi He has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Jing Geng
5 shared publicationsJinghua Wu
5 shared publicationsJuanjuan Shi
5 shared publicationsPing Lu
5 shared publicationsWei Wang
5 shared publicationsYan-Miao Huo
5 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1.Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1.Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-7,Table S1-3 from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Figure S1.Flow cytometry analysis of IL-22RA1 expression among PDAC; Figure S2. The correlation analyses between IL-22RA1 and CSCs Figure S3. IL-22RA1hi pancreatic cancer cells have CSCs properties Figure S4. IL-22RA1hi pancreatic cancer cells express higher EMT markers FigureS5. IL-22 promotes stemness of pancreatic cancer cells FigureS6. IL-6 activates STAT3, but unable to promote stemness of PDACs Figure S7. Dot1L is not involved in IL-22 induced stemness of PDACs Table S1. Quantitative real-time PCR and ChIP primers TableS2&3. The co-relationship between IL-22RA1 expression and PDAC patients characteristics
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-7,Table S1-3 from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Figure S1.Flow cytometry analysis of IL-22RA1 expression among PDAC; Figure S2. The correlation analyses between IL-22RA1 and CSCs Figure S3. IL-22RA1hi pancreatic cancer cells have CSCs properties Figure S4. IL-22RA1hi pancreatic cancer cells express higher EMT markers FigureS5. IL-22 promotes stemness of pancreatic cancer cells FigureS6. IL-6 activates STAT3, but unable to promote stemness of PDACs Figure S7. Dot1L is not involved in IL-22 induced stemness of PDACs Table S1. Quantitative real-time PCR and ChIP primers TableS2&3. The co-relationship between IL-22RA1 expression and PDAC patients characteristics
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1-7,Table S1-3 from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Figure S1.Flow cytometry analysis of IL-22RA1 expression among PDAC; Figure S2. The correlation analyses between IL-22RA1 and CSCs Figure S3. IL-22RA1hi pancreatic cancer cells have CSCs properties Figure S4. IL-22RA1hi pancreatic cancer cells express higher EMT markers FigureS5. IL-22 promotes stemness of pancreatic cancer cells FigureS6. IL-6 activates STAT3, but unable to promote stemness of PDACs Figure S7. Dot1L is not involved in IL-22 induced stemness of PDACs Table S1. Quantitative real-time PCR and ChIP primers TableS2&3. The co-relationship between IL-22RA1 expression and PDAC patients characteristics
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-7,Table S1-3 from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Figure S1.Flow cytometry analysis of IL-22RA1 expression among PDAC; Figure S2. The correlation analyses between IL-22RA1 and CSCs Figure S3. IL-22RA1hi pancreatic cancer cells have CSCs properties Figure S4. IL-22RA1hi pancreatic cancer cells express higher EMT markers FigureS5. IL-22 promotes stemness of pancreatic cancer cells FigureS6. IL-6 activates STAT3, but unable to promote stemness of PDACs Figure S7. Dot1L is not involved in IL-22 induced stemness of PDACs Table S1. Quantitative real-time PCR and ChIP primers TableS2&3. The co-relationship between IL-22RA1 expression and PDAC patients characteristics
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1.Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1.Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.
- 14 June 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (12) , 3293-3305
IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1. Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.
- 14 June 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (12) , 3293-3305
IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer
Chronic inflammation is a feature of pancreatic cancer, but little is known about how immune cells or immune cell–related signals affect pancreatic cancer stemness and development. Our previous work showed that IL22/IL22RA1 plays a vital role in acute and chronic pancreatitis progression by mediating cross-talk between immune cells and acinar cells or stellate cells, respectively. Here, we find IL22RA1 is highly but heterogeneously expressed in pancreatic cancer cells, with high expression associated with poor prognosis of patients with pancreatic cancer. The IL22RA1hi population from pancreatic cancer harbored higher stemness potential and tumorigenicity. Notably, IL22 promoted pancreatic cancer stemness via IL22RA1/STAT3 signaling, establishing the mechanism of regulation of cancer stemness by microenvironmental factors. Moreover, STAT3 was indispensable for the maintenance of IL22RA1hi cells. Overall, these findings provide a therapeutic strategy for patients with PDAC with high expression of IL22RA1. Significance: IL22RA1/STAT3 signaling enhances stemness and tumorigenicity in pancreatic cancer. Cancer Res; 78(12); 3293–305. ©2018 AACR.